Visual performance of small-aperture intraocular lens for extending depth-of-focus in cataract patients

Session Details

Session Title: Pseudophakic IOLs: Enlarged-Depth-of-Focus I

Session Date/Time: Monday 12/09/2016 | 14:00-15:30

Paper Time: 14:24

Venue: Hall C4

First Author: : M.Piovella ITALY

Co Author(s): :    B. Kusa                    

Abstract Details

Purpose:

To demonstrate visual performance of the IC-8 small aperture IOL (AcuFocus, Irvine, CA) implanted in patients in whom a cataractous lens has been removed.The IC8 IOL has centered inside the optic disk the KAMRA inlay that was succesfully studied as monolateral corneal implant to provide near vision

Setting:

C.M.A. Centro Microchirurgia Ambulatoriale Monza, Italy

Methods:

Eyes with cataract , corneal astigmatism ≤ 1.25 , had IC-8 IOL implantation in the non-dominant eye and an aspheric monofocal IOL in the dominant eye.It is not a monovision technique,due to the 20/20 no correction far vision outcomes achieved by the patients. Postoperatively, the following visual and refractive parameters were measured: distance (4m) near (40cm) and intermediate (70 cm) visual acuity, corneal topography and Acutarget analysis, contrast sensitivity and defocus curve. Regular follow-up examinations were performed up to 9 months after surgery.

Results:

We have implanted in 20 Patients,20 IC8 IOLs in the non dominant eye .At 9 months in the IC-8 eye, UDVA is 20/21 ± 2.50 , UIVA is 20/27 ± 13.04 and UNVA is 20/25 ± 4.28 . In the monofocal eye, UDVA is 20/20 ± 0.60 , UIVA is 20/50 ± 12.02 and UNVA is 20/58 ± 24.32. Binocular UDVA is 20/20 ± 2.85, UIVA is 20/ 27 ± 3.12 and UNVA is 20/26 ± 6.90 .

Conclusions:

The IC-8 shows excellent visual performances at 9 months following implantation. The IC-8 IOL demonstrates good far vision ,glare and healos free,and effective vision at intermediate and near distances.We have detect slight less contrast sensitivity for near vision and no penalization related monocular IC8 implant in the non dominant eye and monofocal implant in the dominant eye.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented